Serum immunologic markers in multiple sclerosis patients on continuous combined therapy with beta-interferon 1a,prednisone and azathioprine

Abstract

Break-through symptoms (BTS) in multiple sclerosis (MS) patients on beta-interferon (beta-IFN) monotherapy are most frequently treated with a brief administration of steroids. Here, we report the results of monitoring serum immunologic markers recorded at three-month intervals for 1.5 years in responders to beta-INF 1a (Avonex) monotherapy (n = 21) and MS patients placed on Avonex with prednisone (n = 83) and Avonex, prednisone and azathioprine (AZA) (n = 21) because of BTS. Compared to 23 healthy controls, patients on Avonex monotherapy and Avonex with prednisone, in individuals on Avonex, prednisone and AZA, a significant decrease in serum concentration of soluble intercellular adhesion molecule-1 (sICAM-1) (P = 0.001) was established. Combined therapy with Avonex, prednisone and AZA was associated with a significant increase in the serum level of interleukin (IL)10 (P < 0.001). Compared to Avonex monotherapy, combined therapy suppressed the serum level of IL12p40, antagonized elevation in the serum concentration of soluble IL2 receptor (sIL2R) and inhibited an increase in the serum soluble CD95 (sCD95) molecule. In patients studied, no significant differences in the serum level of IL18 and tumor necrosis factor-α (TNF-α) were established. These findings are important in understanding some of the immunoregulatory mechanisms induced by combined therapy in MS.

Keywords

azathioprine beta-interferon combined therapy glucocorticoids multiple sclerosis serum cytokines

Get full access to this article

View all access options for this article.

References

Lassmann H , Bruck W , Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis; implications for diagnosis and therapy . Trends Mol Med 2001; 7: 115-121 .

Hafler DA , Weiner HL. Immunologic mechanisms and therapy in multiple sclerosis . Immunol Rev 1995; 144: 75-107 .

Khoury SJ , Gutttmann CRG , Orav EJ , Kikinis R , Jolez FA , Weiner HL. Changes in activated T cells in the blood correlate with disease activity . Arch Neurol 2000; 57: 1183-1189 .

van Boxel-Dezaire AHH , Hoff SCJ , van Oosten BW , Verweij CL , Drager AM , Ader HJ , et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis . Ann Neurol 1999; 45: 695-703 .

Hartung HP , Reiners K , Archelos JJ , Michels M , Seeldrayers P , Heidenreich F , et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging . Ann Neurol 1995; 38: 186-193 .

Navikas V , Link H. Cytokines and the pathogenesis of multiple sclerosis . J Neurosci Res 1996; 45: 322-333 .

Giovannoni G , Lai M , Thorpe J , Kidd D , Chamoun V , Thompson AJ , et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging . Neurology 1997; 48: 1557-1565 .

Rieckmann P , Martin S , Weichselbraun I , Albrecht M , Kitze B , Weber T , et al. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse . Neurology 1994; 44: 2367-2372 .

Zipp F , Weller M , Calabresi PA , Frank JA , Bash CN , Dichagans J , et al. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing remitting multiple sclerosis . Ann Neurol 1998; 43: 116-120 .

10.

Balashov KE , Comabella M , Ohashi T , Khoury SJ , Weiner HL. Defective regulation of IFNg and IL-12 by endogenous IL-10 in progressive MS . Neurology 2000; 55: 192-198 .

11.

Nicoletti F , Di Marco R , Mangano K , Patti F , Reggio E , Nicoletti A , et al. Increased serum levels of interleukin-18 in patients with multiple sclerosis . Neurology 2001; 57: 342-344 .

12.

Byrnes AA , McArthur JC , Karp CL. Interferon-β therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production . Ann Neurol 2002; 51: 165-174 .

13.

Adachi K , Kumamoto T , Araki S. Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis . Ann Neurol 1990; 28: 687-691 .

14.

Trebst C , Ransohoff RM. Investigating chemokines and chemokine receptors in patients with multiple sclerosis . Arch Neurol 2001; 58: 1975-1980 .

15.

Sorensen TL , Sellebjerg F. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS . Neurology 2001; 57: 1371-1376 .

16.

van Oosten BW , Barkhoff F , Scholten PET , von Blomberg ME , Ader HJ , Polman CH. Increased production of tumor necrosis factor α, and not of interferon γ, preceding disease activity in patients with multiple sclerosis . Arch Neurol 1998; 55: 793-798 .

17.

van Dissel J , van Langevelde P , Westendorp RG , Kwappenberg K , Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients . Lancet 1998; 351: 950-953 .

18.

Zipp F , Weber F , Huber S , Sotgiu S , Czlonkowska A , Holler E , et al. Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells . Ann Neurol 1995; 38: 723-730 .

19.

De Jong BA , Schrijver HM , Huizinga TWJ , Bollen ELEM , Polman CH , Uitdehaag BMJ , et al. Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis . Ann Neurol 2000; 48: 641-646 .

20.

Wandinger K-P , Sturzebecher C-S , Bielekova B , Detore G , Rosenwald A , Staudt LM , et al. Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes . Ann Neurol 2001; 50: 349-357 .

21.

Hong J , Zang YC , Hutton G , Rivera VM , Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis . J Neuroimmunol 2004; 152: 126-139 .

22.

Trojano M , Avolio C , Simone IL , Defazio G , Manzari C , De Robertis F , et al. Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging enhancement and cerebrospinal fluid findings . Neurology 1996; 47: 1535-1541 .

23.

Elovara I , Ukkomen M , Leppakynnas M , Lehtimaki T , Luomala M , Peltola J , et al. Adhesion molecules in multiple sclerosis. Relation to subtypes of disease and methylprednisolone therapy . Arch Neurol 2000; 57: 546-551 .

24.

Kumpfel T , Gottschalk M , Tollmacher T , Trenkwalder C , Weber F. Changes in cytokine serum levels and white blood cell counts during high-dose glucocorticoid therapy in patients with inflammatory diseases of the nervous system . J Neurol 2002; 1: 172-193 .

25.

Rudick RA , Ransohoff RM , Peppler R , Medendorp SV , Lehmann P , Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis . Ann Neurol 1996; 40: 618-627 .

26.

Salama HH , Kolar OJ , Zang YCQ , Zhang J. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis . Mult Scler 2003; 9: 28-31 .

27.

Calabresi PA , Pelfrey CM , Tranquill LR , Maloni H , McFarland HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta . Neurology 1997; 49: 1111-1116 .

28.

McDonald WI , Compston A , Edan G , Goodkin D , Hartung HP , Lublin FD , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis . Ann Neurol 2001; 50: 121-127 .

29.

Cannella B , Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions . Ann Neurol 1995; 37: 424-435 .

30.

Droogan AG , McMillan SA , Douglas JP , Hawkins SA. Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1 . J Immunol 1996; 64: 185-191 .

31.

Wong D , Prameya R , Dorovini-Zis K. Monoclonal antibodies to endothelial adhesion molecules VCAM-1 and ICAM-1, but not E-selectin, inhibit adhesion of T-lymphocytes to cytokine stimulated human brain micro-vessel endothelial cells in vitro . Brain Pathol 1994; 4: 498-498 .

32.

Gearing JH , Newman W. Circulating adhesion molecules in disease . Immunol Today 1993; 14: 506-512 .

33.

Rose JW , Watt HE , White AT , Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody . Ann Neurol 2004; 56: 864-867 .

34.

Zipp F , Otzelberger K , Dichgans J , Martin R , Weller M. Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis . J Neuroimmunol 1998; 86: 151-154 .

35.

Zipp F , Weller M , Calabresi PA , Frank JA , Bash CN , Dichgans J , et al. Increased serum levels of soluble Cd95 (APO-1/Fas) in relapsing-remitting multiple sclerosis . Ann Neurol 1998; 43: 116-120 .